Entries by Nascent

The Economist: Closing In On Cancer

The Economist has published a fascinating overview of cancer research’s progress, including immunotherapy: The greatest excitement is reserved for immunotherapy, a new approach that has emerged in the past few years. The human immune system is equipped with a set of brakes that cancer cells are able to activate; the first immunotherapy treatment in effect […]

Nascent Biotech Retires Liabilities with Non-Dilutive Funding

Vero Beach FL, August 10, 2016 – Nascent Biotech, Inc., (“Nascent” or “the Company”) (BB: NBIO) is pleased to announce that through the non-dilutive funding recently received, it has paid nearly $1.7 million in payables and debt, plus created positive shareholders equity. “With this funding we are now able to advance our asset through accelerated […]

Nascent Biotech and Hisun Announce an Exclusive License Agreement for the Development and Commercialization of Nascent’s Primary Asset, Pritumumab, in Mainland China

Development planned for multiple Epithelial Cancer Types, starting with brain cancer, in Mainland China. July 18, 2016 10:00 am EDT Dateline: TAIZHOU, Zhejiang Province, China & Vero Beach, FL, USA Public Company Information: OTC: NBIO Taizhou, Zhejiang Province, China & Vero Beach, FL USA.- Nascent Biotech, Inc. (OTC: NBIO), and Zhejiang Hisun Pharmaceutical Company Ltd., […]

Nascent Biotech, Inc. Announces the Addition of Mr. Doug Karas to its Board of Directors

Vero Beach, FL April 14, 2016 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announced today that Doug Karas, Vice President of Performance Analysis & Investment Risk at Franklin Templeton Investments, has joined its Board of Directors. Mr. Karas is a Certified Public Accountant and has extensive accounting, auditing, finance and consulting […]

Nascent Biotech Inc. Announces the Retirement of Its Convertible Debt

San Diego, CA September 17, 2015 – Nascent Biotech, Inc, (“Nascent” or “the Company”) (PINK.BB: NBIO) is pleased to announce that it has retired the $ 60,000 convertible debenture effective yesterday. The convertible debt could have potentially been converted into 6,000,000 shares of the Company’s common stock, thus diluting all the shareholders by nearly 30%. […]

Nascent Biotech Achieves Two Key Milestones in Development of its Novel Brain Cancer Treatment

San Diego, CA August 13, 2015 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO). Since March of 2014 Nascent has raised $2.1 million which has been used to advance the development of their core product, Pritumumab, to support the filing of an Investigational New Drug exemption (IND). Pritumumab is a fully human […]

Nascent Biotech, Inc. President Interviewed by The Stock Radio

San Diego, CA August 12, 2015 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), is pleased to release a recent interview with company President Sean Carrick, on The Stock Radio show.  It can be heard in full at: http://thestockradio.com/otcpink-nbio-nascent-biotech-inc-president-sean-carrick-2239.html In the interview, Mr. Carrick details that Nascent Biotech’s primary asset, Pritumumab, binds to a […]